Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

Waking up exhausted BCMA-specific T cells in myeloma

Antonio Sacco, Aldo M. Roccaro

Blood (2024) 143 (10): 840–841.

https://doi.org/10.1182/blood.2023023037

Published: 2024

Journal Articles

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Blood (2023) 142 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2023-189094

Published: 2023

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

Starving multiple myeloma cells via CDK7 inhibition

Antonio Sacco, Aldo M. Roccaro

Blood (2023) 141 (23): 2787–2788.

https://doi.org/10.1182/blood.2023020254

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136982

Published: 2020

Journal Articles

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN, Cinzia Federico, PhD, Arianna Giacomini, PhD, Cinzia Caprio, PhD, Federica Maccarinelli, PhD, Katia Todoerti, PhD, Vanessa Favasuli, Antonella Anastasia, MD, Marina Motta, MD, Giuseppe Rossi, MD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Antonino Neri, MD, Roberto Ronca, PhD, Chiara Cattaneo, MD, Alessandra Tucci, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MDPhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136523

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2019) 134 (Supplement_1): 1527.

https://doi.org/10.1182/blood-2019-126889

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo

Blood (2018) 132 (Supplement 1): 55.

https://doi.org/10.1182/blood-2018-99-113916

Published: 2018

Journal Articles

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Blood (2017) 130 (Supplement 1): 392.

https://doi.org/10.1182/blood.V130.Suppl_1.392.392

Published: 2017

Journal Articles

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Antonio Sacco, Loredana Affò, Gaia C Ghedini, Gaetana Lanzi, Arianna Giacomini, Marina Motta, Antonella Anastasia, Claudia Ghidini, Marco Chiarini, Silvia Giliani, Roberto Ronca, Luisa Imberti, MD, Alessandro Montanelli, MD, Nicole Bozza, Riccardo Castelli, Giuseppe Rossi, MD, Marco Mor, Marco Presta, Aldo M. Roccaro

Blood (2017) 130 (Supplement 1): 2818.

https://doi.org/10.1182/blood.V130.Suppl_1.2818.2818

Published: 2017

NARROW

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Waking up exhausted BCMA-specific T cells in myeloma

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Starving multiple myeloma cells via CDK7 inhibition

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only